Why Jilin Jian Yisheng Pharmaceutical's (SZSE:002566) Shaky Earnings Are Just The Beginning Of Its Problems
Why Jilin Jian Yisheng Pharmaceutical's (SZSE:002566) Shaky Earnings Are Just The Beginning Of Its Problems
Jilin Jian Yisheng Pharmaceutical Co., Ltd.'s (SZSE:002566) recent weak earnings report didn't cause a big stock movement. However, we believe that investors should be aware of some underlying factors which may be of concern.
吉林健益生药业有限公司s(SZSE:002566)最近疲软的收益报告并未导致股市大幅波动。但是,我们认为,投资者应注意一些可能令人担忧的潜在因素。
How Do Unusual Items Influence Profit?
不寻常的物品如何影响利润?
Importantly, our data indicates that Jilin Jian Yisheng Pharmaceutical's profit received a boost of CN¥35m in unusual items, over the last year. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. Jilin Jian Yisheng Pharmaceutical had a rather significant contribution from unusual items relative to its profit to September 2024. As a result, we can surmise that the unusual items are making its statutory profit significantly stronger than it would otherwise be.
重要的是,我们的数据表明,去年吉林健益生制药的不寻常项目利润增加了3500万元人民币。虽然我们希望看到利润增加,但当不寻常的物品做出重大贡献时,我们往往会更加谨慎一些。当我们分析全球绝大多数上市公司时,我们发现重大不寻常的事项往往不会重演。而且,毕竟,这正是会计术语的含义。截至2024年9月,吉林健益生药业因不寻常项目而对利润做出了相当大的贡献。因此,我们可以推测,这些不寻常的物品使其法定利润明显高于原来的水平。
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Jilin Jian Yisheng Pharmaceutical.
注意:我们始终建议投资者检查资产负债表的实力。点击此处查看我们对吉林健益生制药的资产负债表分析。
Our Take On Jilin Jian Yisheng Pharmaceutical's Profit Performance
我们对吉林健益生制药盈利表现的看法
As previously mentioned, Jilin Jian Yisheng Pharmaceutical's large boost from unusual items won't be there indefinitely, so its statutory earnings are probably a poor guide to its underlying profitability. For this reason, we think that Jilin Jian Yisheng Pharmaceutical's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. In further bad news, its earnings per share decreased in the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you want to do dive deeper into Jilin Jian Yisheng Pharmaceutical, you'd also look into what risks it is currently facing. Case in point: We've spotted 2 warning signs for Jilin Jian Yisheng Pharmaceutical you should be aware of.
如前所述,吉林健益生制药不会无限期地从不寻常项目中获得巨额提振,因此其法定收益可能无法指导其潜在盈利能力。出于这个原因,我们认为吉林健益生药业的法定利润可能不利于其潜在盈利能力,并可能给投资者留下过于积极的公司印象。另一个坏消息是,其每股收益在去年有所下降。当然,我们只是在分析其收益时才浮出水面;人们还可以考虑利润率、预测增长和投资回报率等因素。如果你想更深入地了解吉林健益生药业,你还需要研究它目前面临的风险。一个很好的例子:我们发现了吉林健益生药业的两个警告信号,你应该注意了。
Today we've zoomed in on a single data point to better understand the nature of Jilin Jian Yisheng Pharmaceutical's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
今天,我们放大了单一数据点,以更好地了解吉林健益生制药利润的性质。但是,如果你能够将注意力集中在细节上,总会有更多的事情需要发现。例如,许多人认为高股本回报率是有利的商业经济的标志,而另一些人则喜欢 “关注资金”,寻找内部人士正在买入的股票。虽然可能需要你进行一些研究,但你可能会发现这份免费收集的拥有高股本回报率的公司,或者这份拥有大量内幕持股的股票清单很有用。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?担心内容吗?直接联系我们。或者,发送电子邮件给编辑组(网址为)simplywallst.com。
Simply Wall St 的这篇文章本质上是笼统的。我们仅使用公正的方法提供基于历史数据和分析师预测的评论,我们的文章并非旨在提供财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不会考虑最新的价格敏感型公司公告或定性材料。华尔街只是没有持有上述任何股票的头寸。